We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Sensitive Detection Method Identifies Protein Clumps in Parkinson’s Disease Skin Samples

By LabMedica International staff writers
Posted on 02 Nov 2020
A sensitive detection method usually used to identify aggregated prion proteins has been adapted for the diagnosis of Parkinson's disease in skin samples.

An unmet clinical need in Parkinson's disease (PD) has been the identification of biomarkers for diagnosis, preferably in easily accessible tissues such as skin. More...
In this regard previous immunohistochemical studies have detected pathological clumping of alpha‐synuclein (aSyn) protein in skin biopsies from PD patients.

To identify aSyn aggregates in skin samples, investigators at Iowa State University (Ames, USA) used a real‐time quaking‐induced conversion assay. Real-time quaking-induced conversion (RT-QuIC) is a highly sensitive assay generally used for prion detection. The "quaking" in the name of the technique refers to the fact that samples in the RT-QuIC assay are literally subjected to shaking. This action breaks apart aggregates of prion protein (PrP) that are then further incubated, amplifying the amount of misfolded PrP to detectable levels.

The investigators adapted the RT-QuIC assay to determine the seeding kinetics of the aSyn present in the skin from autopsied subjects consisting of frozen skin tissues from 25 PD and 25 controls and formalin‐fixed paraffin‐embedded skin sections from 12 PD and 12 controls.

Results of the analysis revealed that the assay had correctly identified 24/25 PD and 24/25 controls using frozen skin tissues (96% sensitivity and 96% specificity) compared to 9/12 PD and 10/12 controls using formalin‐fixed paraffin‐embedded skin sections (75% sensitivity and 83% specificity). These results clearly demonstrated the feasibility of using skin tissues for clinical diagnosis of PD by detecting pathological aSyn.

"Since there is no easy and reliable test available for the early diagnosis of Parkinson's disease at present, we think there will be a lot interest in the potential use of skin samples for diagnosis," said senior author Dr. Anumantha Kanthasamy, professor of biomedical sciences at Iowa State University. "Testing skin samples could lead to earlier detection of Parkinson's disease. Earlier diagnosis could allow physicians to test therapeutic strategies designed to slow or prevent the development of advanced symptoms."

The skin test paper was published in the September 22, 2020, online edition of the journal Movement Disorders.

Related Links:
Iowa State University


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.